Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in late spermatids | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 348 | 0.85 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9828
Sealed predictions
- SLC16A1 in dopamine neurons, braak+0.38 (p 0.309) → +0.08 (p 0.842)receipt 9836
- SLC16A1 in oligodendrocytes, braak+0.13 (p 0.739) → -0.26 (p 0.502)receipt 9835
Swarm cases
receipt 9836: SLC16A1 in dopamine neurons, braak
- power
- full sample +0.26 (p 0.289, n 18), 95% CI -0.23 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.27 (p 0.273, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.23 (p 0.365, n 18). could be the mix.
- skeptic
- leave-one-out range +0.17 to +0.42, sign flips 0; without severely affected donors +0.26 (p 0.289, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC16A1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 9835: SLC16A1 in oligodendrocytes, braak
- power
- full sample -0.03 (p 0.908, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.02 (p 0.942, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.06 (p 0.827, n 18). could be the mix.
- skeptic
- leave-one-out range -0.17 to +0.08, sign flips 7; without severely affected donors -0.03 (p 0.908, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC16A1 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts